OBJECTIVES:  This meta-analysis was carried out to assess the efficacy and safety of albiglutide (30mg subcutaneous injection administered once a week) compared to any control intervention (other anti-diabetic medication, or placebo) among patients with T2DM. METHODS:  Literature searches were conducted in Pubmed, Embase and The Cochrane library databases. In addition, Clinicaltrials.gov was also searched to obtain additional information. Studies retrieved from the databases were screened and data were extracted by single reviewer, then cross checked for accuracy by second reviewer. Randomized controlled trials assessing the efficacy and safety of albiglutide among T2DM patients with ≥18 years old were included in this meta-analysis. Data were pooled using random-effect model (RevMan5.3). RESULTS:  Of the 323 studies retrieved through database search, 10 (N=5613) met the eligibility criteria. Albiglutide was found to be effective in reducing glycated hemoglobin (HbA1c) (weighted mean difference [WMD], -0.62; 95% confidence interval [CI], -0.91 to -0.32; n=10), and fasting blood glucose (FBG) levels (WMD, -1.51; 95% CI,-1.81 to -1.8; n=6) than the control intervention. No significant differences were observed in hypoglycemia (risk ratio [RR], 1.01; 95% CI, 0.73 to 1.4; n=9), hypertension (RR, 1.04; 95% CI, 0.68 to 1.58; n=3), coronary artery disease (RR, 0.73; 95% CI, 0.33 to 1.63; n=6), unstable angina (RR, 0.49; 95% CI;0.16 to 1.49; n=4), and any gastrointestinal (GI) events (RR, 1.10; 95% CI, 0.79 to 1.53; n=5) between two groups. But, there was more than two fold increased risk of developing injection site reactions in the albiglutide group when compared to the control group (RR, 2.31; 95% CI 1.13 to 4.72; n=9). CONCLUSIONS:  Meta-analysis suggests that albiglutide is effective and safe among patients with T2DM. However, albiglutide appears to be associated with the risk of injection site reactions. In future more well designed randomized controlled trials with long-term follow-up are needed to establish this.